Huntington’s Disease: Protein Breakdown Key to Potential Therapy – Ruhr University Bochum Study

Currently, there is no cure for Huntington’s disease: a genetic alteration leads to the formation of defective proteins that accumulate and cause the typical symptoms. A team from the Human Genetics department at Ruhr University Bochum has demonstrated the role of targeted ubiquitin marking at two positions on the mutated huntingtin protein for its degradation and distribution within the cell. The findings, published today, February 5, 2026, could offer an approach for future therapeutic intervention.

The Importance of Protein Clearance

Huntington’s disease is a rare, but severe, inherited disorder. The cause lies in a mutation of the huntingtin gene. This alteration results in the production of an altered form of the huntingtin protein, which is encoded by the gene. “It contains extended glutamine chains, which cause the protein to misfold and thus cannot perform its function correctly,” explains Huu Phuc Nguyen, head of the Department of Human Genetics at Ruhr University Bochum. Misfolded proteins pose a danger to the body and must be broken down. However, the altered huntingtin protein is not efficiently eliminated, but accumulates. This eventually leads to symptoms such as movement disorders, dementia, and psychiatric abnormalities in patients. “There is currently no cure for Huntington’s disease. All affected individuals eventually die from it,” says Huu Phuc Nguyen.

Together with his team and international partners, the human geneticist is investigating the fundamentals of the disease and attempting to uncover the underlying mechanisms. In the current work, the researchers took a close look at the degradation of the proteins involved. “Before a damaged or misfolded protein can be broken down, it must first be marked and transported to the degradation complex within the cell,” Nguyen explains. “In the case of the huntingtin protein, ubiquitin marking at two specific sites, positions K6 and K9, plays a crucial role in the degradation and distribution of the protein within the cell.” Once marked, the proteins are transported to the so-called proteasome, the central protein degradation system of the cell, and eliminated there.

Blocking the Marking Site Worsens the Disease

The researchers were able to observe this process in cell culture in a previous study. In the current work, they replaced the mouse huntingtin gene in a special knock-in mouse model with a human, disease-causing variant. In a further mouse line, the binding sites K6 and K9 of the huntingtin protein were also altered so that no ubiquitin marking was possible there. “We were able to observe that this significantly worsened the symptoms of Huntington’s disease,” reports Huu Phuc Nguyen. “The signs of the disease also appeared earlier than in mice that only carried the huntingtin mutation.”

The researchers, who collaborated with Prof. Dr. Aaron Ciechanover, who was awarded the 2004 Nobel Prize in Chemistry for his work on the protein degradation system, hope that this finding will provide a starting point for therapeutic intervention against the disease. “Knowledge of the key sites for marking could make it possible to stimulate the degradation process for damaged huntingtin protein,” says Nguyen. “We suspect that the mutated protein escapes the degradation process because the disease-related structural change and a disturbed ubiquitin marking at crucial positions impair its degradation.”

The huntingtin protein is expressed throughout the body and involved in several key molecular and cellular mechanisms. Further research is needed to fully understand the complex interplay between the mutated protein, ubiquitin marking, and the development of Huntington’s disease. The study, published in Proceedings of the National Academy of Sciences on January 8, 2026, represents a significant step forward in understanding the pathogenesis of this devastating disease.

While the research is preliminary, it highlights the potential for targeting protein degradation pathways as a therapeutic strategy. Further studies are needed to determine whether stimulating ubiquitin marking and proteasomal degradation can effectively slow or halt the progression of Huntington’s disease in humans.